Ralph Hester, MD
Ophthalmology · Oklahoma City, OKNPI 1215904974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $631 and has fallen 62.9% since, to $234 in 2025.
Across 116 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$257
- Sight Sciences, Inc.$193
- Kala Pharmaceuticals, Inc.$174
- Harrow Eye, LLC$141
- AbbVie$137
- Ocular Therapeutix, Inc.$115
- plus $921 from 14 others
What the payments were for
- Food & beverage$1,939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 21 | $257 |
| Sight Sciences, Inc. | 10 | $193 |
| Kala Pharmaceuticals, Inc. | 19 | $174 |
| Harrow Eye, LLC | 6 | $141 |
| AbbVie(2 entities) | 9 | $137 |
| Ocular Therapeutix, Inc. | 7 | $115 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $113 |
| Bausch & Lomb Americas Inc. | 6 | $107 |
| Shire North American Group Inc | 4 | $97 |
| Aerie Pharmaceuticals, Inc. | 5 | $96 |
| Alcon | 4 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $80 |
| The Cameron-ehlen Group, Inc. | 2 | $73 |
| Rxsight Inc | 4 | $72 |
| Novartis | 4 | $69 |
| Dompe US, Inc. | 2 | $45 |
| Eyevance Pharmaceuticals LLC | 2 | $31 |
| Glaukos Corporation | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $13 |
How this compares
$1,939 in reported general payments places this provider in the 65th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $33,479 |
| LumiganBimatoprost | 48 | $22,401 |
| FlarexFluorometholone Acetate | 113 | $14,157 |
| CequaCyclosporine | 13 | $9,812 |
| XiidraLifitegrast | 14 | $8,517 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $6,973 |
| Ofloxacin | 368 | $4,535 |
| Latanoprost | 407 | $4,387 |
| Fluorometholone | 45 | $3,737 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 275 | $3,302 |
| Brimonidine Tartrate | 29 | $1,195 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $310 |
| ErythromycinErythromycin Base | 21 | $240 |
| Timolol Maleate | 18 | $139 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $137 | $55,88072 claims |
| Eyevance Pharmaceuticals LLCFlarex | $31 | $14,157113 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $257 | $9,81213 claims |
| Bausch & Lomb Americas Inc.Xiidra | $107 | $8,51714 claims |
| AlconSimbrinza | $85 | $6,97327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Oklahoma City
- Ronald RebenitschOklahoma City$141K
- Edward JonesOklahoma City$13K
- John BelardoOklahoma City$12K
- David KorberOklahoma City$11K
- Jason NguyenOklahoma City$9K
- Annie ChanOklahoma City$6K
- Lance ScottOklahoma City$5K
- Craig EckOklahoma City$5K
- Valerie LobodiakOklahoma City$4K
- Clifton FayOklahoma City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.